摘要
人参皂苷(Ginsenoside,GS)具有多种心血管药理作用,也显示出抗血小板作用。目前研究显示,人参总皂苷、GS-Re、GS-Rg1、GS-Rk1、GS-Rg3及GS-Rg3衍生物GS-Rp1均具有抗血小板作用。GS能够提高抗血小板药物治疗效果,可能是现代血栓栓塞性疾病药物治疗的重要补充。应用miRNA等新技术、分子模块等新观点等可以指导GS的抗血小板研究。
Multifunctions of ginsenoside（GS）,including antiplatelet effect,has been found in protecting cardiovascular system. Current evidence supports the antiplatelet effect of total GSs,GS-Re、GS-Rg1、GS-Rk1、GS-Rg3,and GSRp1,a derivative of GS-Rg3. GS reinforces antiplatelet drugs＇ function,providing its role as a potential drug candidate for thromboembolism diseases. New technology and modern perspective would guide the future research.
作者
郑思道
刘韶英
谢芳
ZHENG Si-dao;LIU Shao-ying;XIE Fang(Department of Cardiology,Beijing Hospital of Integrated Traditional Chinese and Western Medicine, Beijing 100039, China)
出处
《中国现代中药》
CAS
2018年第5期631-634,共4页
Modern Chinese Medicine
基金
北京市优秀人才培养资助青年骨干个人项目(2014000057592G296)
